China Approval For Akeso’s Bispecific But ASCO Data Unnerve Investors

 
• By Dexter Jie Yan
  
China pharma US trial
Akeso's ivonescimab faces twisty road to efficacy superiority over rivals • Source: Shutterstock

More from China

More from Focus On Asia